Amgen Gets Cost-Sharing, MedImmune A Pipeline Boost In Five-Antibody Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen and the AstraZeneca biologics subsidiary will co-develop and commercialize five monoclonal antibodies in inflammation and respiratory indications, led by brodalumab, which recently posted impressive Phase II data in psoriasis.
You may also be interested in...
Deal Watch: Endo Hopes To Boost Generics Unit With Buy-Out Of Par
J&J is teaming with Achillion to produce a combo regimen for hepatitis C that might compete with offerings from Gilead, AbbVie and Merck. Amgen is dropping out of its collaboration on brodalumab with AstraZeneca due to concerns about suicidality in clinical trials.
Amgen Bows Out Of Partnership With AstraZeneca On Phase III Brodalumab
Company drops deal to co-develop and commercialize the IL-17 blocker in psoriasis, cites reports of suicidal ideation.
Soriot Makes Changes At AstraZeneca As The Pharma Explores Its Options
AstraZeneca’s Soriot makes big moves on his first day on the job – putting a hold on the company’s share-repurchase program and causing speculation that a big acquisition is set for the near future.